Aiolos Bio is a clinical stage biopharma company dedicated to pioneering transformative treatments for respiratory disease and immunological disorders. Based in the San Francisco Bay area with operations in London, UK, the company's seasoned team has a track record of successfully developing and launching products for various immune conditions like asthma, rheumatoid arthritis, and IPF. Their current focus is on developing a groundbreaking anti-TSLP therapy with best-in-class potential to significantly reduce treatment burden for patients and caregivers. The company recently secured a $245.00M Series A investment on 24 October 2023 from prominent investors including Atlas Venture, RA Capital Management, Forbion, Sofinnova Investments, and Bain Capital Life Sciences. Aiolos Bio's commitment to making a meaningful difference in the lives of patients suffering from respiratory illnesses and immune disorders positions them as an intriguing prospect for potential investors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $245.00M | 5 |
|
24 Oct 2023 |
We care about your data, and we'd love to use cookies make your experience better.
